Skip to main content

Selank









Selank


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search























































Selank
Selank.png
Clinical data
Synonyms Selanc; L-threonyl-L-lysyl-L-prolyl-L-arginyl-L-prolylglycyl-L-Proline
Routes of
administration		 Nasal muscosa, IV
Legal status
Legal status

  • In general: unscheduled
Identifiers
CAS Number

  • 129954-34-3 ☒N

PubChem CID
  • 11765600
ChemSpider

  • 9940290 ☑Y
Chemical and physical data
Formula
C33H57N11O9
Molar mass 751.89 g·mol−1
3D model (JSmol)
  • Interactive image

.mw-parser-output .nobold{font-weight:normal}
 ☒N☑Y (what is this?)
  (verify)

Selank (Russian: Cеланк) is a nootropic, anxiolytic peptide based drug developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is a synthetic analogue of human tuftsin.




Contents






  • 1 Pharmacology


  • 2 Clinical trials


  • 3 See also


  • 4 References


  • 5 External links





Pharmacology[edit]


Selank is a synthetic analogue of the immunomodulatory peptide tuftsin; as such, it mimics many of its effects. It has been shown to modulate the expression of Interleukin-6 (IL-6) and affect the balance of T helper cell cytokines.[1] It has been shown to influence the concentration of monoamine neurotransmitters[2] and induce metabolism of serotonin.[3][4] Selank has also been found to rapidly elevate the expression of brain-derived neurotropic factor (BDNF) in the hippocampus of rats.[5]


Selank, as well as a related peptide drug, Semax, have been found to inhibit enzymes involved in the degradation of enkephalins and other endogenous regulatory peptides, and this action may be involved in their effects.[6] It has also been found to affect the activity of carboxypeptidase H and phenylmethylsulfonylfluoride-inhibited carboxypeptidase in rat nervous system tissue.[7]


Selank has been found to produce antidepressant-like effects in animal models of depression and anhedonia.[8]



Clinical trials[edit]


In clinical trials, the drug has shown to provide a sustained nootropic and anxiolytic effect which is useful for the treatment of generalized anxiety disorder (GAD).[1] Selank has an advantage over traditional anxiety treatments, such as benzodiazepines, as it has no sedating or negative cognitive side effects and no associated addiction or withdrawal problems.


Selank is closely related to another nootropic drug, Semax, also developed by the Institute of Molecular Genetics in Russia. This drug is currently available in Russian and Ukrainian pharmacies.[9]


As with all lyophilized peptides, it needs refrigeration to remain stable within sterile water solutions, such as bacteriostatic water concentrations.



See also[edit]



  • Afobazole

  • Mebicar

  • Semax



References[edit]





  1. ^ ab Uchakina, O. N.; Uchakin, P. N.; Miasoedov, N. F.; Andreeva, L. A.; Shcherbenko, V. E.; Mezentseva, M. V.; Gabaeva, M. V.; Sokolov, O. U.; Zozulia, A. A.; Ershov, F. I. (2008). "Immunomodulatory effects of selank in patients with anxiety-asthenic disorders". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov. 108 (5): 71–75. PMID 18577961..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ Narkevich, VB; Kudrin, VS; Klodt, PM; Pokrovskiĭ, AA; Kozlovskaia, MM; Maĭskiĭ, AI; Raevskiĭ, KS (2008). "Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study". Eksperimental'naia i klinicheskaia farmakologiia. 71 (5): 8–12. PMID 19093364.


  3. ^ Semenova, T. P.; Kozlovskiĭ, I. I.; Zakharova, N. M.; Kozlovskaia, M. M. (2010). "Experimental optimization of learning and memory processes by selank". Eksperimental'naia i klinicheskaia farmakologiia. 73 (8): 2–5. PMID 20919548.


  4. ^ Semenova, T. P.; Kozlovskiĭ, I. I.; Zakharova, N. M.; Kozlovskaia, M. M. (2009). "Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA". Eksperimental'naia i klinicheskaia farmakologiia. 72 (4): 6–8. PMID 19803361.


  5. ^ Inozemtseva, LS; Karpenko, EA; Dolotov, OV; Levitskaya, NG; Kamensky, AA; Andreeva, LA; Grivennikov, IA (2008). "Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo". Doklady Biological Sciences. 421: 241–3. doi:10.1134/s0012496608040066. PMID 18841804.


  6. ^ Kost NV; Sokolov OIu; Gabaeva MV; et al. (2001). "Semax and selank inhibit the enkephalin-degrading enzymes from human serum". Bioorg. Khim. (in Russian). 27 (3): 180–3. doi:10.1023/A:1011373002885. PMID 11443939.


  7. ^ Solov'ev VB, Gengin MT, Sollertinskaia TN, Latynova IV, Zhivaeva LV (2012). "[Effect of selank on the main carboxypeptidases in the rat nervous tissue]". Zh. Evol. Biokhim. Fiziol. (in Russian). 48 (3): 254–7. PMID 22827026.


  8. ^ Sarkisova KIu, Kozlovskiĭ II, Kozlovskaia MM (2008). "[Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice]". Zh Vyssh Nerv Deiat Im I P Pavlova (in Russian). 58 (2): 226–37. PMID 18661785.


  9. ^ Institute of Molecular Genetics: Translation of Archived 2011-07-22 at the Wayback Machine.




External links[edit]


  • Selank instructions














Retrieved from "https://en.wikipedia.org/w/index.php?title=Selank&oldid=840534792"





Navigation menu

























(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.868","walltime":"1.083","ppvisitednodes":{"value":5829,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":267730,"limit":2097152},"templateargumentsize":{"value":7548,"limit":2097152},"expansiondepth":{"value":17,"limit":40},"expensivefunctioncount":{"value":3,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":25320,"limit":5000000},"entityaccesscount":{"value":2,"limit":400},"timingprofile":["100.00% 706.765 1 -total"," 50.78% 358.917 1 Template:Drugbox"," 36.10% 255.155 1 Template:Infobox"," 24.00% 169.627 1 Template:Reflist"," 19.26% 136.127 8 Template:Cite_journal"," 14.93% 105.498 13 Template:Navbox"," 10.91% 77.123 16 Template:Unbulleted_list"," 8.65% 61.133 1 Template:Refimprove"," 5.94% 41.960 1 Template:Ambox"," 5.55% 39.215 1 Template:Neuropeptidergics"]},"scribunto":{"limitreport-timeusage":{"value":"0.271","limit":"10.000"},"limitreport-memusage":{"value":5804625,"limit":52428800}},"cachereport":{"origin":"mw1253","timestamp":"20181222051902","ttl":1900800,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":93,"wgHostname":"mw1263"});});
-

Popular posts from this blog

Full-time equivalent

Image
Full-time equivalent From Wikipedia, the free encyclopedia Jump to navigation Jump to search Full-time equivalent ( FTE ) or whole time equivalent ( WTE ) is a unit that indicates the workload of an employed person (or student) in a way that makes workloads or class loads comparable [1] across various contexts. FTE is often used to measure a worker's or student's involvement in a project, or to track cost reductions in an organization. An FTE of 1.0 is equivalent to a full-time worker or student, while an FTE of 0.5 signals half of a full work or school load. [2] Contents 1 U.S. Federal Government 2 In education 2.1 Example 3 Notes 4 References U.S. Federal Government [ edit ] In the U.S. Federal Government, FTE is defined by the Government Accountability Office (GAO) as the number of total hours worked divided by the maximum number of compensable hours in a full-time schedule as...
Read more

さくらももこ

Image
さくら ももこ 本名 非公開 [1] 生誕 ( 1965-05-08 ) 1965年5月8日 日本・静岡県清水市 （現・静岡市清水区） 死没 ( 2018-08-15 ) 2018年8月15日（53歳没） 日本・東京都目黒区 国籍 日本 職業 漫画家 エッセイスト 作詞家 活動期間 1984年 - 2018年 ジャンル 少女漫画 青年漫画 児童漫画 代表作 『ちびまる子ちゃん』 『コジコジ』 受賞 1989年：第13回講談社漫画賞少女部門 （『ちびまる子ちゃん』） 1990年：第32回日本レコード大賞 （『おどるポンポコリン』作詞） 公式サイト さくらプロダクション テンプレートを表示 さくら ももこ （1965年5月8日 - 2018年8月15日 [2] ）は、日本の漫画家、エッセイスト、作詞家、脚本家。また、自身の少女時代をモデルとした代表作のコミック『ちびまる子ちゃん』の主人公の名前でもある。静岡県清水市（現・静岡市清水区）出身。血液型はA型。身長159cm。一男の母親。 代表作のコミック『ちびまる子ちゃん』の単行本の売上は累計3000万部を超える。また、エッセイストとしても独特の視点と語り口で人気が高く、初期エッセイ集三部作『もものかんづめ』『さるのこしかけ』『たいのおかしら』はいずれもミリオンセラーを記録。 目次 1 経歴 2 人物・交遊関係 3 主な作品 3.1 漫画 3.2 エッセイ 3.3 作詞 3.4 詩集 3.5 雑誌・ムック本 3.6 翻訳 3.7 絵本、ドラマ脚本他 3.8 ラジオ出演 3.9 その他 4 関係人物 4.1 アシスタント 4.2 さくらももこを演じた人物 5 脚注 5.1 注釈 5.2 出典 6 外部リンク 経歴 年譜形式の経歴は推奨されていません 。人物の伝記は流れのあるまとまった文章で記述し、年譜は補助的な使用にとどめてください。 （ 2018年8月 ） 清水市立（当時）入江小学校...
Read more

13 indicted, 8 arrested in Calif. drug cartel investigation

Image
Fox News U.S. World Opinion Politics Entertainment Business Lifestyle TV Radio More Expand / Collapse search Login Watch TV ☰ Hot Topics U.S. Crime Military Education Terror Immigration Economy Personal Freedoms World U.N. Conflicts Terrorism Disasters Global Economy Environment Religion Scandals Opinion Politics Executive Senate House Judiciary Foreign policy Polls Elections Entertainment Celebrity News Movies TV News Music News Style News Entertainment Video Business Markets Politics Technology Features Business Leaders Lifestyle Food + Drink Cars + Trucks Travel + Outdoors House + Home Fitness + Well-being Style + Beauty Family Science Archaeology Air & Space Planet Earth Wild Nature Natural Science Dinosaurs Tech Security Innovation Drones Computers Video Games Military Tech Health Healthy Living Medical Research Mental Health Cancer Heart Health Children'...
Read more